Efficacy of natalizumab in multiple sclerosis patients with high disease activity: A Danish nationwide study

European Journal of Neurology

Volumn 16, Issue 3, 2009, Pages 420-423

  Oturai, A B ^a   Koch Henriksen, N ^a,b   Petersen, T ^c   Jensen, P E H ^a   Sellebjerg, F ^a   Sorensen, P S ^a  

^a Rigshospitalet   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antibodies; High disease activity; Mitoxantrone; Multiple sclerosis; Natalizumab

Indexed keywords

ANTIBODY; CLEMASTINE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB;

ADULT; ANAPHYLAXIS; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; POPULATION RESEARCH; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE;

ADOLESCENT; ADULT; ANAPHYLAXIS; ANTIBODIES, MONOCLONAL; DENMARK; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROPROTECTIVE AGENTS; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 60049091373     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02517.x     Document Type: Article

References (8)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine 2006 354 : 899 910.
2. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. New England Journal of Medicine 2006 354 : 911 923.
3. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. New England Journal of Medicine 2006 354 : 924 933.
4. Dorsey ER, Thompson JP, Noyes K, Dick AW, Holloway RG, Schwid SR. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis. Neurology 2007 68 : 1524 1528.
5. Kappos L, Bates D, Hartung HP, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007 6 : 431 441.
6. Calabreci PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab-antibodies: results from AFFIRM and SENTINEL. Neurology 2007 69 : 1391 1403.
7. EMEA. Home Page, Section 5.1, Tysabri Product Information: Annex I: Summary of Product Characteristics. http://www.emea.europa.eu/humandocs/PDFs/ EPAR/tysabri/H-603-PI-en.pdf (accessed 27/12/2008).
8. Centonze D, Furlan R, Gasperin C, et al. Early relapses after the first dose of natalizumab in active multiple sclerosis patients. Multiple sclerosis 2008 14 : 1137 1138.